Oral fingolimod (FTY720) treatment reduces peripheral IL-17-producing TH17 cells in patients with multiple sclerosis

被引：0
|
作者：
Mehling, Matthias [1 ,2 ]
Lindberg, Raija L. [1 ,2 ]
Kuhle, Jens [1 ,2 ]
Vedrine, Corinne [3 ]
Kappos, Ludwig [1 ,2 ]
Brinkmann, Volker [3 ]
机构：
[1] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland
[3] Novartis Inst Biomed Res, Basel, Switzerland
来源：
MULTIPLE SCLEROSIS | 2008年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S234 / S234
页数：1
相关论文
共 50 条
  • [41] From natural product to the first oral treatment of multiple sclerosis: The discovery of FTY720(Gilenya™)
    Zecri, Frederic
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [42] Oral fingolimod (FTY720) therapy reduces blood brain barrier breakdown, microglial activation, and leukocyte recruitment in a focal DTH model of multiple sclerosis
    Anthony, D. C.
    Sibson, N. R.
    Losey, P.
    Piani, D.
    Leppert, D.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S275 - S276
  • [43] Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis
    Sato, Douglas Kazutoshi
    Nakashima, Ichiro
    Bar-Or, Amit
    Misu, Tatsuro
    Suzuki, Chihiro
    Nishiyama, Shuhei
    Kuroda, Hiroshi
    Fujihara, Kazuo
    Aoki, Masashi
    JOURNAL OF NEUROIMMUNOLOGY, 2014, 268 (1-2) : 95 - 98
  • [44] Levels of peripheral Th17 cells and serum Th17-related cytokines in patients with multiple sclerosis: A meta-analysis
    Li, Yu-Feng
    Zhang, Sheng-Xiao
    Ma, Xiao-Wen
    Xue, Yu-Long
    Gao, Chong
    Li, Xin-Yi
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 20 - 25
  • [45] Dopamine favors expansion of glucocorticoid-resistant IL-17-producing T cells in multiple sclerosis
    Ferreira, Thais B.
    Barros, Priscila O.
    Teixeira, Bruna
    Cassano, Tatiane
    Centuriao, Newton
    Kasahara, Taissa M.
    Hygino, Joana
    Vasconcelos, Claudia Cristina F.
    Alvarenga Filho, Helcio
    Alvarenga, Regina
    Wing, Ana Cristina
    Andrade, Regis M.
    Andrade, Arnaldo F.
    Bento, Cleonice A. M.
    BRAIN BEHAVIOR AND IMMUNITY, 2014, 41 : 182 - 190
  • [46] Characterization of Th17 cells in multiple sclerosis patients and healthy controls
    Buehler, Ulrike
    Gollan, Rene
    Belikan, Patrick
    Zipp, Frauke
    Siffrin, Volker
    JOURNAL OF NEUROIMMUNOLOGY, 2014, 275 (1-2) : 140 - 141
  • [47] Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study
    Montalban, X.
    Comi, G.
    O'Connor, P.
    Gold, S. M.
    de Vera, A.
    Eckert, B.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (11) : 1341 - 1350
  • [48] CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis
    Jin, Yi
    Zollinger, Markus
    Borell, Hubert
    Zimmerlin, Alfred
    Patten, Christopher J.
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (02) : 191 - 198
  • [49] Effects of Catecholamines on Th17 Cells in Multiple Sclerosis
    Mel’nikov M.V.
    Belousova O.O.
    Zhetishev R.R.
    Pashchenkov M.V.
    Boiko A.N.
    Neuroscience and Behavioral Physiology, 2018, 48 (3) : 342 - 345
  • [50] IL-17-Producing CCR6+CD4+ Th17 Cells Drive Intestinal Allograft Rejection in Humans.
    Kaiser, J.
    Cosentino, C.
    Shukla, A.
    Desai, C.
    Girlanda, R.
    Hawksworth, J.
    Matsumoto, C.
    Zasloff, M.
    Fishbein, T.
    Kroemer, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 396 - 397
12345